Other
Sprain
32
Pipeline Programs↗
1
Active Trials↗
16
Companies Involved↗
Sprain is a moderately active landscape with 32 programs across 16 companies. The most active players are Cerimon Pharmaceuticals, Pfizer, APR Applied Pharma Research s.a.. 16 therapies are approved with 12 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical3
Phase 1
No programs
Phase 312
Analysis
Trial Status
38
clinical trials
Completed29 · 76%
Terminated4 · 11%
Unknown status3 · 8%
Withdrawn1 · 3%
Active, not recruiting1 · 3%
Clinical Trials
Trial Activity
38 trials
Topical Treatments for Ankle Sprains
Active, not recruiting·—·N/A·NCT06623929·100 enrolled
Open Label Comparative Study On Celecoxib Efficacy And Safety Vs Non-Selective NSAID In Acute Pain Due To Ankle Sprain
Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00446797·278 enrolled
Injection of Corticoids for the Treatment of Acute Sprains of the Proximal Interphalangeal Joints of the Fingers.
Completed·—·Phase 2·NCT02916940·60 enrolled
Topical Ketoprofen Versus Placebo in Patients With Ankle Sprain
Completed·—·Phase 4·NCT02393846·100 enrolled
Approach to Ankle Sprains in the Emergency Department
Completed·—·Phase 4·NCT06563271·150 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)